{
    "url_original": "https://www.wsj.com/articles/pfizer-begins-study-testing-omicron-vaccine-in-people-11643111101?mod=business_lead_pos2",
    "url": "pfizer-begins-study-testing-omicron-vaccine-in-people-11643111101",
    "title": "Pfizer Begins Study Testing Omicron Vaccine in People",
    "sub_head": "The company and partner BioNTech say the trial will examine safety and immune response, in case regulators deem an adapted vaccine necessary",
    "category_1": "Health",
    "time": "2022-01-25 06:45:00",
    "body": "Pfizer Inc. and  BioNTech SE  have started a trial evaluating an adapted version of their Covid-19 vaccine that targets the Omicron variant of the coronavirus.<br />The drugmakers said Tuesday they began enrolling adults ages 18 to 55 in the U.S. and South Africa to examine the safety, tolerability and immune response generated by the vaccine if it is given either as a primary series or as a booster dose."
}